[Donanemab, an Amyloid β-targeting Antibody for Early Symptomatic Alzheimer's Disease: Summary of Clinical Study Results].

Le résumé fourni par la source

Alzheimer's disease is an age-related neurodegenerative disorder, and is considered to contribute to dementia in 60%-70% of individuals with dementia. In recent years, a series of amyloid β protein (Aβ)-targeting antibodies that act directly on Aβ aggregates in the brain, one of the factors which contributes to the onset of Alzheimer's disease, have been approved to suppress the clinical progression, and Alzheimer's disease treatment in Japan is changing. This review article focuses on one of these Aβ-targeting antibodies, donanemab, and summarizes its clinical study results. (Received November 1, 2024; Accepted May 7, 2025; Published August 1, 2025).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.